JUPITER NEUROSCIENCES, INC. 8-K/A Filing

From the Filing

0001493152-25-024454.txt : 20251120 0001493152-25-024454.hdr.sgml : 20251120 20251120160528 ACCESSION NUMBER: 0001493152-25-024454 CONFORMED SUBMISSION TYPE: 8-K/A PUBLIC DOCUMENT COUNT: 14 CONFORMED PERIOD OF REPORT: 20251024 ITEM INFORMATION: Entry into a Material Definitive Agreement ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20251120 DATE AS OF CHANGE: 20251120 FILER: COMPANY DATA: COMPANY CONFORMED NAME: JUPITER NEUROSCIENCES, INC. CENTRAL INDEX KEY: 0001679628 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences EIN: 474828381 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K/A SEC ACT: 1934 Act SEC FILE NUMBER: 001-41265 FILM NUMBER: 251503076 BUSINESS ADDRESS: STREET 1: 1001 NORTH US HWY 1 STREET 2: SUITE 504 CITY: JUPITER STATE: FL ZIP: 33477 BUSINESS PHONE: (561) 406-6154 MAIL ADDRESS: STREET 1: 1001 NORTH US HWY 1 STREET 2: SUITE 504 CITY: JUPITER STATE: FL ZIP: 33477 FORMER COMPANY: FORMER CONFORMED NAME: Jupiter Orphan Therapeutics, Inc. DATE OF NAME CHANGE: 20160713 8-K/A 1 form8-ka.htm 8-K/A true 0001679628 0001679628 2025-10-24 2025-10-24 iso4217:USD xbrli:shares iso4217:USD xbrli:shares       UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549   FORM 8-K/A   CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934   October 24, 2025 Date of Report (Date of earliest event reported)   JUPITER NEUROSCIENCES, INC. (Exact name of registrant as specified in its charter)   Delaware   001-41265   47-4828381 (State or other jurisdiction   (Commission   (IRS Employer of incorporation)   File Number)   Identification No.)   1001 North US HWY 1 , Suite 504 , Jupiter , FL   33477 (Address of principal executive offices)   (Zip Code)   (561) 406-6154 Registrant’s telephone number, including area code   Check the appropriate box below if the Form 8-K is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:   ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)     ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)     ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))     ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))   Securities registered pursuant to Section 12(b) of the Act:   Title of each class   Trading Symbol(s)   Name of each exchange on which registered Common Stock   JUNS   Nasdaq Capital Market   Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).   Emerging Growth Company ☒   If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐             EXPLANATORY NOTE   Jupiter Neurosciences, Inc., a Delaware corporation (the “Company”), is filing this Amendment No. 1 (the “Amended 8-K Report”) to its Current Report on Form 8-K originally filed with the Securities and Exchange Commission (the “SEC”) on October 27, 2025 (the “Original 8-K Report”) to amend and update Item 1.01 of the Original 8-K Report. The Original 8-K Report reported, among other things, the entry into a Standby Equity Purchase Agreement (the “SEPA”) by and betwee